Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-09-25 00:00:00 ET · period of report 2024-09-23 · accession 0002001011-24-000089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-09-25 | 2024-09-23 | LGND | Reardon Andrew | CLO, Sec | M - OptEx | $52.27 | +2,000 | 24.5K | +9% | +$104.5K |
| D | 2024-09-25 | 2024-09-23 | LGND | Reardon Andrew | CLO, Sec | S - Sale+OE | $99.60 | -2,000 | 22.5K | -8% | -$199.2K |
| D | 2024-09-25 | 2024-09-23 | LGND | Reardon Andrew | CLO, Sec | M - OptEx | $0.00 | -2,000 | 70.9K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-23 | M | A | 2,000 | $52.27 | 24,534 | D | — | — | |
| 2 | Common | Common Stock | 2024-09-23 | S | D | 2,000 | $99.60 | 22,534 | D | — | — | |
| 3 | Derivative | Employee Stock Option (right to buy) | 2024-09-23 | M | D | 2,000 | $0.00 | 70,944 | D | $52.27 · — to 2032-08-01 | 2,000 Common Stock | (F1) The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. |